Qureight is an end-to-end imaging CRO company on a mission to accelerate clinical trials. We provide enterprise-grade imaging and precision endpoints for the biopharmaceutical industry. Our AI-powered data and imaging curation platform permits the analysis of clinical imaging and other healthcare data from patients with lung and heart disease, helping our customers bring treatments to market, faster. We provide automated image management and AI analysis in therapeutic areas such as Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Bronchiectasis, and Pulmonary Hypertension. Our world-leading team of scientists, engineers and clinicians is based in Cambridge, UK.
Qureight: Venture Capital Funding History
Qureight
Qureight
- Life Sciences
- Cambridge, United Kingdom
- £15m
- qureight.com
- Update Information
More venture news
- 5 Nov 2026

Alethio TherapeuticsAlethio Therapeutics secures a £67m Series A round led by Sofinnova Partners and RA Capital to develop targeted blood cancer therapies
Series ALife Sciences - 5 Nov 2026

Potential SciencesPotential Sciences launches from stealth with an eight figure investment led by UK Sovereign AI Fund and Twin Path Ventures for its frontier lab for chemistry
EquityLife Sciences - 26 Oct 2026

adsilicoadsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices
Series ALife Sciences
